Sionna Therapeutics (NASDAQ:SION) Receives "Sell (D)" Rating from Weiss Ratings

Key Points

• Sionna Therapeutics received a "sell (d)" rating from Weiss Ratings, indicating a negative outlook from the analysts.
• The company has a consensus rating of "Moderate Buy" among analysts with a target price of $38.00, reflecting mixed reviews from various research firms.
• Sionna's stock has fluctuated significantly, with a 52-week low of $7.26 and a high of $30.60, currently trading at around $28.50.

Sionna Therapeutics (NASDAQ:SION - Get Free Report)'s stock had its "sell (d)" rating reiterated by research analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

A number of other research firms have also recently commented on SION. Royal Bank Of Canada assumed coverage on shares of Sionna Therapeutics in a research note on Wednesday, September 3rd. They set a "sector perform" rating and a $22.00 target price on the stock. Jones Trading assumed coverage on shares of Sionna Therapeutics in a research report on Monday, September 8th. They set a "buy" rating and a $46.00 price objective on the stock. Raymond James Financial assumed coverage on shares of Sionna Therapeutics in a research report on Tuesday, September 2nd. They set a "strong-buy" rating and a $45.00 price objective on the stock. Finally, Wall Street Zen upgraded shares of Sionna Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $38.00.

Sionna Therapeutics Stock Down 0.4%

Shares of NASDAQ SION opened at $28.50 on Wednesday. The firm's 50-day moving average price is $23.67 and its 200-day moving average price is $17.60. Sionna Therapeutics has a 52-week low of $7.26 and a 52-week high of $30.60.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.27.

Insider Activity at Sionna Therapeutics

In other Sionna Therapeutics news, Director Bruce Booth sold 66,105 shares of Sionna Therapeutics stock in a transaction on Monday, September 29th. The shares were sold at an average price of $30.09, for a total transaction of $1,989,099.45. Following the completion of the transaction, the director directly owned 796,259 shares of the company's stock, valued at $23,959,433.31. The trade was a 7.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Elena Ridloff sold 16,098 shares of Sionna Therapeutics stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $25.97, for a total transaction of $418,065.06. Following the transaction, the chief financial officer directly owned 48,116 shares of the company's stock, valued at $1,249,572.52. The trade was a 25.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 211,239 shares of company stock valued at $6,047,807. 3.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Siren L.L.C. purchased a new position in Sionna Therapeutics during the first quarter worth $3,400,000. Zimmer Partners LP purchased a new position in Sionna Therapeutics during the first quarter worth $2,484,000. Goldman Sachs Group Inc. purchased a new position in Sionna Therapeutics during the first quarter worth $667,000. Alyeska Investment Group L.P. purchased a new position in Sionna Therapeutics during the first quarter worth $1,948,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in Sionna Therapeutics during the first quarter worth $676,000.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.